PE20231175A1 - Inmunoterapia oncolitica por remodelacion del microambiente tumoral - Google Patents
Inmunoterapia oncolitica por remodelacion del microambiente tumoralInfo
- Publication number
- PE20231175A1 PE20231175A1 PE2023001681A PE2023001681A PE20231175A1 PE 20231175 A1 PE20231175 A1 PE 20231175A1 PE 2023001681 A PE2023001681 A PE 2023001681A PE 2023001681 A PE2023001681 A PE 2023001681A PE 20231175 A1 PE20231175 A1 PE 20231175A1
- Authority
- PE
- Peru
- Prior art keywords
- remodeling
- oncolytic viruses
- oncolytic
- immunotherapy
- disclosure
- Prior art date
Links
- 238000009169 immunotherapy Methods 0.000 title abstract 2
- 230000000174 oncolytic effect Effects 0.000 title abstract 2
- 238000007634 remodeling Methods 0.000 title abstract 2
- 230000001173 tumoral effect Effects 0.000 title 1
- 244000309459 oncolytic virus Species 0.000 abstract 4
- 206010028980 Neoplasm Diseases 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- 239000000203 mixture Substances 0.000 abstract 1
- 238000012986 modification Methods 0.000 abstract 1
- 230000004048 modification Effects 0.000 abstract 1
- 150000007523 nucleic acids Chemical class 0.000 abstract 1
- 102000039446 nucleic acids Human genes 0.000 abstract 1
- 108020004707 nucleic acids Proteins 0.000 abstract 1
- 238000012385 systemic delivery Methods 0.000 abstract 1
- 230000003612 virological effect Effects 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/66—Microorganisms or materials therefrom
- A61K35/76—Viruses; Subviral particles; Bacteriophages
- A61K35/768—Oncolytic viruses not provided for in groups A61K35/761 - A61K35/766
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/86—Viral vectors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/195—Chemokines, e.g. RANTES
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/20—Interleukins [IL]
- A61K38/2013—IL-2
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/2264—Obesity-gene products, e.g. leptin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/52—Cytokines; Lymphokines; Interferons
- C07K14/54—Interleukins [IL]
- C07K14/55—IL-2
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/575—Hormones
- C07K14/5759—Products of obesity genes, e.g. leptin, obese (OB), tub, fat
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/715—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
- C07K14/7158—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons for chemokines
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/14—Hydrolases (3)
- C12N9/24—Hydrolases (3) acting on glycosyl compounds (3.2)
- C12N9/2402—Hydrolases (3) acting on glycosyl compounds (3.2) hydrolysing O- and S- glycosyl compounds (3.2.1)
- C12N9/2474—Hyaluronoglucosaminidase (3.2.1.35), i.e. hyaluronidase
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/24011—Poxviridae
- C12N2710/24111—Orthopoxvirus, e.g. vaccinia virus, variola
- C12N2710/24132—Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/24011—Poxviridae
- C12N2710/24111—Orthopoxvirus, e.g. vaccinia virus, variola
- C12N2710/24141—Use of virus, viral particle or viral elements as a vector
- C12N2710/24143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/24011—Poxviridae
- C12N2710/24111—Orthopoxvirus, e.g. vaccinia virus, variola
- C12N2710/24171—Demonstrated in vivo effect
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Genetics & Genomics (AREA)
- General Health & Medical Sciences (AREA)
- Zoology (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biophysics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Gastroenterology & Hepatology (AREA)
- Wood Science & Technology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Virology (AREA)
- Toxicology (AREA)
- Biomedical Technology (AREA)
- General Engineering & Computer Science (AREA)
- Biotechnology (AREA)
- Microbiology (AREA)
- Epidemiology (AREA)
- Immunology (AREA)
- Obesity (AREA)
- Endocrinology (AREA)
- Child & Adolescent Psychology (AREA)
- Physics & Mathematics (AREA)
- Cell Biology (AREA)
- Mycology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Oncology (AREA)
- Plant Pathology (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Abstract
La divulgacion se relaciona con virus oncoliticos modificados. Los virus oncoliticos modificados de la divulgacion comprenden la modificacion en el genoma viral que codifica acidos nucleicos exogenos para potenciar la inmunoterapia oncolitica por la remodelacion del microambiente tumoral y con un suministro sistemico potenciado. La divulgacion se relaciona ademas con composiciones que comprenden los virus oncoliticos modificados, kits que los contienen, y metodos para el uso de los virus oncoliticos
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US202063116004P | 2020-11-19 | 2020-11-19 | |
PCT/US2021/059887 WO2022109133A1 (en) | 2020-11-19 | 2021-11-18 | Oncolytic immunotherapy by tumor micro-environment remodeling |
Publications (1)
Publication Number | Publication Date |
---|---|
PE20231175A1 true PE20231175A1 (es) | 2023-08-01 |
Family
ID=81709792
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PE2023001681A PE20231175A1 (es) | 2020-11-19 | 2021-11-18 | Inmunoterapia oncolitica por remodelacion del microambiente tumoral |
Country Status (17)
Country | Link |
---|---|
US (1) | US20230256041A1 (es) |
EP (1) | EP4247410A1 (es) |
JP (1) | JP2023552289A (es) |
KR (1) | KR20230110545A (es) |
CN (1) | CN116801899A (es) |
AU (1) | AU2021385059A1 (es) |
CA (1) | CA3197371A1 (es) |
CL (1) | CL2023001450A1 (es) |
CO (1) | CO2023006544A2 (es) |
CR (1) | CR20230268A (es) |
DO (1) | DOP2023000098A (es) |
EC (1) | ECSP23045508A (es) |
IL (1) | IL302897A (es) |
MX (1) | MX2023005853A (es) |
PE (1) | PE20231175A1 (es) |
TW (1) | TW202227621A (es) |
WO (1) | WO2022109133A1 (es) |
Family Cites Families (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
ZA842025B (en) * | 1983-03-21 | 1984-11-28 | Hoffmann La Roche | Interleuken-2 |
EP2062023B2 (en) * | 2006-08-25 | 2016-11-09 | The Government of the United States of America, as represented by the Secretary, Department of Health and Human Services | Intergenic sites between conserved genes in the genome of modified vaccinia ankara (mva) vaccinia virus |
EP2184297A1 (en) * | 2008-11-07 | 2010-05-12 | Hla-G Technologies | HLA-G polypeptides and pharmaceutical uses thereof |
US11185586B2 (en) * | 2016-11-22 | 2021-11-30 | Alloplex Biotherapeutics, Inc. | Allogeneic tumor cell vaccine |
CA3081436A1 (en) * | 2017-10-31 | 2019-05-09 | Western Oncolytics Ltd. | Platform oncolytic vector for systemic delivery |
KR20200116086A (ko) * | 2018-01-26 | 2020-10-08 | 유니버시티 오브 피츠버그 - 오브 더 커먼웰쓰 시스템 오브 하이어 에듀케이션 | 종양 치료를 개선하기 위한 종양 미세환경에서 대사 조절인자의 발현 |
-
2021
- 2021-11-18 CN CN202180091007.7A patent/CN116801899A/zh active Pending
- 2021-11-18 AU AU2021385059A patent/AU2021385059A1/en active Pending
- 2021-11-18 IL IL302897A patent/IL302897A/en unknown
- 2021-11-18 MX MX2023005853A patent/MX2023005853A/es unknown
- 2021-11-18 TW TW110143069A patent/TW202227621A/zh unknown
- 2021-11-18 JP JP2023529962A patent/JP2023552289A/ja active Pending
- 2021-11-18 WO PCT/US2021/059887 patent/WO2022109133A1/en active Application Filing
- 2021-11-18 EP EP21895584.7A patent/EP4247410A1/en active Pending
- 2021-11-18 PE PE2023001681A patent/PE20231175A1/es unknown
- 2021-11-18 CA CA3197371A patent/CA3197371A1/en active Pending
- 2021-11-18 CR CR20230268A patent/CR20230268A/es unknown
- 2021-11-18 KR KR1020237019985A patent/KR20230110545A/ko unknown
-
2023
- 2023-02-03 US US18/105,374 patent/US20230256041A1/en active Pending
- 2023-05-17 CO CONC2023/0006544A patent/CO2023006544A2/es unknown
- 2023-05-17 DO DO2023000098A patent/DOP2023000098A/es unknown
- 2023-05-19 CL CL2023001450A patent/CL2023001450A1/es unknown
- 2023-06-19 EC ECSENADI202345508A patent/ECSP23045508A/es unknown
Also Published As
Publication number | Publication date |
---|---|
AU2021385059A1 (en) | 2023-06-08 |
IL302897A (en) | 2023-07-01 |
CN116801899A (zh) | 2023-09-22 |
DOP2023000098A (es) | 2023-08-15 |
CA3197371A1 (en) | 2022-05-27 |
JP2023552289A (ja) | 2023-12-15 |
ECSP23045508A (es) | 2023-07-31 |
TW202227621A (zh) | 2022-07-16 |
CR20230268A (es) | 2023-07-26 |
CL2023001450A1 (es) | 2023-10-20 |
KR20230110545A (ko) | 2023-07-24 |
MX2023005853A (es) | 2023-06-02 |
WO2022109133A1 (en) | 2022-05-27 |
EP4247410A1 (en) | 2023-09-27 |
US20230256041A1 (en) | 2023-08-17 |
CO2023006544A2 (es) | 2023-05-19 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CL2019002912A1 (es) | Métodos para detectar aav. (divisional solicitud 201900392). | |
CL2017002731A1 (es) | Adenovirus oncolítico que codifica una proteína b7 | |
MX2019000252A (es) | Administracion viral oncolitica pseudotipada de polipeptidos terapeuticos. | |
BR112019001737A2 (pt) | expressão de pten-long com vírus oncolíticos | |
AR110632A1 (es) | Vectores del adenovirus canino | |
CO2017007105A2 (es) | Nuevos virus de tilapia | |
UY36522A (es) | Ultracentrifugación analítica para la caracterización de partículas virales recombinantes | |
CL2018000164A1 (es) | Vector recombinante del virus orf. | |
CO2021012583A2 (es) | Anticuerpos y métodos para el tratamiento de la infección por influenza a | |
CO2021013417A2 (es) | Arn del replicón-lnp oncolítico sintético y usos para la inmunoterapia contra el cáncer | |
AR101468A1 (es) | Vacuna en vector recombinante de adenovirus aviar serotipo 9 | |
AR069885A1 (es) | Metodos para producir el virus de estomatitis vesicular (vsv) atenuado en un cultivo celular y para mejorar el empaque del vsv de propagacion defectuosa, composicion inmunogenica, celula aislada y secuencia de control transcripcional | |
PE20231175A1 (es) | Inmunoterapia oncolitica por remodelacion del microambiente tumoral | |
CO2021009271A2 (es) | Rhabdovirus recombinante que codifica ccl21 | |
AR072150A1 (es) | Metodo de replicacion del virus de la influenza en suspension | |
CL2018002042A1 (es) | Metodos para la produccion de virus. | |
AR117808A1 (es) | Virus de vacuna recombinante y métodos de uso del mismo | |
CO2023014507A2 (es) | Virus oncolíticos para la expresión modificada del mhc | |
AR119105A1 (es) | Célula mutante bloqueada mdbk irf3 / irf7 y su uso para producción de vacunas | |
AR122385A1 (es) | VACUNA BASADA EN POXVIRUS RECOMBINANTES CONTRA EL VIRUS SARS-CoV-2 | |
CL2022001176A1 (es) | Composiciones y métodos para producir una vacuna viral con tamaño de partícula reducida | |
CL2019003108A1 (es) | Obtención de una salmonela enteritidis tipo rugosa y sus modificaciones genéticas para uso como vacuna aviar. | |
CL2019003911A1 (es) | Vacuna antitumoral que comprende cuerpos celulares, atp y polimixina b; y uso combinado de cuerpos celulares, atp y polimixina b para potenciar la respuesta antitumoral activando células dendríticas. | |
AR114410A1 (es) | Vacuna multivalente contra influenza viva atenuada para prevenir y controlar el virus influenza equino (vie) en caballos | |
AR072555A1 (es) | Vacuna adenoviral recombinante para elvirus de la leucemia felina y uso de la misma |